The STI1-Depletion Decoupling Hypothesis: Age-Related Chaperone Network Collapse is Driven by an Imbalance Between Disaggregation and Degradation Kinetics

Recent evidence fundamentally redefines our understanding of age-associated proteostasis collapse. The classical view of a uniform, systemic decline in chaperone abundance is inaccurate; instead, the failure is topological and kinetic. It is driven by the selective dysregulation of co-chaperones like STI1, leading to downstream loss of CHIP, Pin1, and CypA without altering core chaperone expression.

I propose the STI1-Depletion Decoupling Hypothesis: The age-dependent decline of the STI1 bridging co-chaperone does not merely slow overall protein folding, but actively generates toxic intermediates by decoupling HSP70-mediated disaggregation from HSP90/CHIP-mediated degradation.

Mechanistic Framework

We know that the Hsc70/Hsp70 system can directly disaggregate α-synuclein fibrils by extracting monomeric units from fibril ends. In a healthy state, STI1 acts as the critical kinetic scaffold, seamlessly coordinating the handoff of these newly liberated, highly aggregation-prone monomers from HSP70 to HSP90 and its associated ubiquitin ligase, CHIP, for immediate proteasomal destruction.

However, when STI1 protein levels naturally decline significantly between young and old mice, this pipeline breaks. Because core HSP70 levels remain robust, fibril disassembly continues unabated. But the secondary 40% reduction in CHIP—caused by the loss of the STI1 scaffold—creates a severe kinetic bottleneck. The liberated monomers are stranded. Lacking the structural shielding of the HSP90 cavity and the ubiquitination activity of CHIP, these unchaperoned monomers rapidly re-nucleate into soluble oligomers, which are vastly more neurotoxic than the mature fibrils themselves.

This mechanism elegantly explains the cumulative network overload observed in neurodegeneration. The system doesn't just passively fail to fold new proteins; its residual, uncoupled disaggregation activity actively feeds a pool of rogue oligomers that aberrantly interact with and sequester other native proteins.

Furthermore, this decoupling likely extends to intercellular proteostasis. Because chaperones including Hsp40, Hsp70, and Hsp90 are physiologically secreted via exosomes, a cell experiencing STI1 depletion will secrete exosomes packed with "incomplete" chaperone machineries—specifically, HSP70 capable of disaggregation but lacking the STI1/CHIP components necessary for degradation. This would propagate the disaggregation-degradation imbalance to neighboring healthy cells, offering a novel explanation for the trans-cellular spread of proteostasis failure.

Testable Predictions and Falsifiability

This hypothesis is readily falsifiable through the following experimental paradigms:

1. In Vitro Kinetic Assays: Incubate mature α-synuclein fibrils with a reconstituted HSP70/HSP90/CHIP system. Gradually titrate down STI1 concentrations. If the hypothesis holds, we should observe a biphasic shift: a steady decrease in mature fibrils accompanied by an exponential spike in soluble toxic oligomers (quantifiable via A11 antibody dot blots or single-molecule FRET), directly correlating with the degree of STI1 depletion.
2. Exosomal Propagation Profiling: Isolate exosomes from STI1-haploinsufficient astrocytes. The hypothesis predicts these exosomes will exhibit an abnormally high HSP70:CHIP ratio. Applying these exosomes to naive neurons loaded with benign α-synuclein fibrils should paradoxically increase cellular toxicity by fragmenting fibrils into oligomers without providing the necessary degradative capacity.
3. In Vivo Rescue Dynamics: Using aged murine models, modulating specific co-chaperones like STI1 or enhancing proteasomal degradation via CHIP should yield distinct results. Restoring CHIP independently of STI1 will only partially rescue neurodegeneration, whereas restoring the physical linking capacity of STI1 is strictly required to re-couple HSP70 disaggregation to downstream degradation.

Therapeutically, this suggests that enhancing core HSP70 expression without concurrent STI1/CHIP support could be actively detrimental in aged tissue. Proteostasis therapies must focus on restoring stoichiometric balance across the entire chaperone handoff, not just boosting primary disaggregation capacity.